We are live on
!
Find out more
Dianthus Therapeutics
DNTH
DNTH
45 hedge funds and large institutions have $22M invested in Dianthus Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
0.07% less ownership
Funds ownership: 3.06% → 2.99% (-0.07%)
7% less capital invested
Capital invested by funds: $23.6M → $22M (-$1.56M)
12% less funds holding
Funds holding: 51 → 45 (-6)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
45
Holders Change
-6
Holders Change %
-11.76%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
3
Increased
10
Reduced
12
Closed
9
Calls
$11K
Puts
–
Net Calls
+$11K
Net Calls Change
+$8K
Top Buyers
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.55M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.38M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
+$391K |
| 4 |
Renaissance Technologies
New York
|
+$62.8K |
| 5 |
CCM
Corsair Capital Management
New York
|
+$47.7K |
Top Sellers
| 1 |
LPC
Lion Point Capital
New York
|
-$3.62M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.29M |
| 3 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$1.14M |
| 4 |
TG
TCW Group
Los Angeles,
California
|
-$596K |
| 5 |
Morgan Stanley
New York
|
-$356K |
